The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Another Agent, a triple GIP/GLP-1/GCG receptor agonist https://sparxsocial.com/story479909/retatrutide-and-nicotinamide-adenine-dinucleotide-a-integrated-system-to-metabolic-wellness